Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study
- PMID: 20472675
- PMCID: PMC2871073
- DOI: 10.1136/bmj.c2205
Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study
Abstract
Objective: To estimate the risk and probability of heterosexual transmission of HIV-1 from infected people taking combined antiretroviral treatment.
Design: Cross sectional and prospective cohort studies.
Setting: HIV clinic in Madrid, Spain.
Participants: Stable heterosexual couples with one partner with HIV-1 infection (index partner) and the other reporting this sexual relationship as the only risk exposure.
Main outcome measures: HIV seroprevalence in non-index partners at enrolment and seroconversions in follow-up according to antiretroviral treatment taken by the index partner.
Results: In 476 couples in which the index partner was not taking antiretroviral treatment, HIV seroprevalence at enrolment in non-index partners was 9.2% (n=44), whereas in 149 couples in which the index partner was taking combined antiretroviral therapy no partner was infected (P<0.001). During follow-up, the 341 serodiscordant couples in which the index partner was not taking antiretroviral treatment had about 11 000 acts of intercourse without condoms, 50 natural pregnancies, and five HIV seroconversions (0.0004 per unprotected intercourse; 95% confidence interval 0.0001 to 0.0010); 294 of these couples always used condoms, accounting for about 42 000 acts of intercourse, 136 risk exposures from condom failure, and one HIV seroconversion. The relative risk associated with condom use was 0.07 (0.01 to 0.58). In 144 couples the index partner was taking combined antiretroviral treatment; they accounted for over 7000 unprotected acts of intercourse and 47 natural pregnancies but no HIV seroconversion (0 to 0.0005 per unprotected intercourse).
Conclusions: The heterosexual infectivity of HIV-1 in individuals taking effective antiretroviral treatment is low. Avoidance of unprotected intercourse and receipt of antiretroviral treatment by the infected partner in accordance with protocols are complementary measures to prevent HIV transmission.
Conflict of interest statement
Competing interests: All authors have completed the Unified Competing Interest form at
Figures
Comment in
-
HIV transmission in serodiscordant heterosexual couples.BMJ. 2010 May 26;340:c2449. doi: 10.1136/bmj.c2449. BMJ. 2010. PMID: 20504846 No abstract available.
References
-
- De Vincenzi I for the European Group on Heterosexual Transmission of HIV. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. N Engl J Med 1994;331:341-6. - PubMed
-
- Saracco A, Musicco M, Nicolosi A, Angarano G, Arici C, Gavazzeni G, et al. Man-to-woman sexual transmission of HIV: longitudinal study of 343 steady partners of infected men. J Acquir Immune Defic Syndr 1993;6:497-502. - PubMed
-
- Padian NS, Shiboski SC, Glass SO, Vittinghoff E. Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: results from a ten-year study. Am J Epidemiol 1997;146:350-7. - PubMed
-
- Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005;191:1403-9. - PubMed
-
- Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001;357:1149-53. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical